BOSTON, July 9, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma, a global company that offers radiopharmaceuticals and radiopharmacies for nuclear medicine, announce the expansion of their strategic partnership and licensing agreement to provide and distribute Neuraceq® from Jubilant's single photon emission computed tomography (SPECT) and Positron Emision Tomography (PET) radiopharmaceutical manufacturing site located in Mobile, AL. The first doses have been made available on July 9th, 2024.
BOSTON, April 5, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Cleveland, Ohio. The first doses have been made available on April 4, 2024.
BOSTON, Jan. 9, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Houston, Texas. The first doses will be available on January 9th, 2023.